Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Challenges in the search for drugs to treat central nervous system disorders.

Enna SJ, Williams M.

J Pharmacol Exp Ther. 2009 May;329(2):404-11. doi: 10.1124/jpet.108.143420. Epub 2009 Jan 30.

2.
3.

Receptorome screening for CNS drug discovery.

Vortherms TA, Roth BL.

IDrugs. 2005 Jun;8(6):491-6. Review.

PMID:
15906196
4.

Multifunctional receptor-directed drugs for disorders of the central nervous system.

Buccafusco JJ.

Neurotherapeutics. 2009 Jan;6(1):4-13. doi: 10.1016/j.nurt.2008.10.031. Review.

PMID:
19110195
5.

Modulation of the vasopressin system for the treatment of CNS diseases.

Ryckmans T.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):538-47. Review.

PMID:
20812145
6.

Opportunities and challenges in the discovery of new central nervous system drugs.

Krause JE, Chenard BL.

Ann N Y Acad Sci. 2008 Nov;1144:243-50. doi: 10.1196/annals.1418.024.

PMID:
19076381
7.

Overview of the use of transgenic animals in CNS drug discovery.

Nestler EJ, Olivier B.

Curr Protoc Pharmacol. 2001 May;Chapter 5:Unit5.20. doi: 10.1002/0471141755.ph0520s07.

PMID:
21965073
8.

CNS drug development - lost in translation?

Talevi A, Bellera CL, Di Ianni M, Gantner M, Bruno-Blanch LE, Castro EA.

Mini Rev Med Chem. 2012 Sep 1;12(10):959-70. Review.

PMID:
22420574
9.

The role of pharmacogenetics in treating central nervous system disorders.

Patnaik M, Renda MJ, Athanasiou MC, Reed CR.

Exp Biol Med (Maywood). 2008 Dec;233(12):1504-9. doi: 10.3181/0806-S-195. Epub 2008 Oct 10.

PMID:
18849543
10.

A role for fMRI in optimizing CNS drug development.

Borsook D, Becerra L, Hargreaves R.

Nat Rev Drug Discov. 2006 May;5(5):411-24. Review.

PMID:
16604100
11.

The potential of antisense as a CNS therapeutic.

Godfray J, Estibeiro P.

Expert Opin Ther Targets. 2003 Jun;7(3):363-76. Review.

PMID:
12783572
12.
13.
14.

Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.

Cole PE, Schwarz AJ, Schmidt ME.

Clin Pharmacol Ther. 2012 Feb;91(2):315-20. doi: 10.1038/clpt.2011.286. Epub 2012 Jan 4. Review.

PMID:
22218072
15.

Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.

Macauley D, Al-Shamahi A.

IDrugs. 2009 Jan;12(1):17-9. No abstract available.

PMID:
19127499
16.

Prediction of CNS activity of compound libraries using substructure analysis.

Engkvist O, Wrede P, Rester U.

J Chem Inf Comput Sci. 2003 Jan-Feb;43(1):155-60.

PMID:
12546548
17.

Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.

Brunner D, Balc─▒ F, Ludvig EA.

Behav Processes. 2012 Feb;89(2):187-95. doi: 10.1016/j.beproc.2011.10.011. Epub 2011 Dec 7. Review.

PMID:
22155361
18.

Translational CNS medicines research.

Palmer AM, Alavijeh MS.

Drug Discov Today. 2012 Oct;17(19-20):1068-78. doi: 10.1016/j.drudis.2012.05.001. Epub 2012 May 10. Review.

PMID:
22580061
19.

Correct assessment of new compounds using in vivo screening models can reduce false positives.

Bueters TJ, Hoogstraate J, Visser SA.

Drug Discov Today. 2009 Jan;14(1-2):89-94. doi: 10.1016/j.drudis.2008.09.003. Epub 2008 Oct 22. Review.

PMID:
18840543
20.

CNS drug discovery: challenges and solutions.

Palmer AM, Stephenson FA.

Drug News Perspect. 2005 Jan-Feb;18(1):51-7.

PMID:
15753976
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk